肺原性心脏病患者骨代谢的改变  

Variations of bone metabolism in patients with pulmonary heart disease

作　　者：白孟海[1] 葛宝丰[1] 郭永忠[1] 高梅[1] 陈克明[1] 王琦[1] 刘剑梅[1] 

机构地区：[1]兰州军区兰州总医院创伤外科研究所,甘肃兰州730050

出　　处：《中国骨伤》2003年第2期65-66,共2页China Journal of Orthopaedics and Traumatology

摘　　要：目的　通过对肺原性心脏病患者尿脱氧吡啶酚的测定了解骨代谢情况。方法　采用酶联免疫法测定了 2 3例肺心病 (男 13例 ,女 10例 )患者的尿脱氧吡啶酚浓度与 2 3例正常人进行比较。结果　肺原性心脏病患者与对照组的尿脱氧吡啶酚排泄率分别为 :男 :95 82± 3 6 11,66 80± 2 1 97(t =2 417) ;女 :10 3 99± 3 4 47,65 79± 2 1 98(t=3 0 3 7)。肺心病患者的尿脱氧吡啶酚排泄率与对照组比较差异有显著性 (P <0 0 5 )。结论　肺原性心脏病患者 ,由于长期慢性缺氧等因素 ,致尿脱氧吡啶酚水平明显增高。Objective To study diagnostic value of urine deoxypyridinoline for the detection of bone metabolism in cases of pulmonary heart disease Methods Urine deoxypyridinoline was assayed by ELISA in 23 patients of pulmonary heart disease (males 13,females 10) and 23 normal persons served as control.Results The urine deoxypyridinoline of males was 95.82±36.11 and of control group 66.80±21.97 (t=2.417).In the females,it was 103.99±34.47 and 65.79±21.98(t=3.307) respectively.All the data had significant difference with the results of control group.Conclusion The urine deoxypyridinoline of patients with pulmonary heart disease was higher because of the long period of chronic lack of oxygen indicating an increased rate of bone absorption.

关 键 词：肺原性心脏病 骨代谢 尿脱氧吡啶酚 酶联免疫吸附 测定 

分 类 号：R541.5[医药卫生—心血管疾病]